Intrathecal cytarabine and bone marrow suppression.
Barişta
I
I
D000380:Agranulocytosis / Q000139:chemically induced*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D006801:Humans; D007278:Injections, Spinal; D008581:Meningitis / Q000188:drug therapy; D009369:Neoplasms / Q000150:complications
D000964:Antimetabolites, Antineoplastic; D003692:Delayed-Action Preparations; D003561:Cytarabine